Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

RA Capital Reports New 5.8% Position In Recently Public Versartis Inc (VSAR)

Peter Kolchinsky’s RA Capital Management has initiated a new position in Versartis Inc (NASDAQ:VSAR). RA Capital owns 1.40 million shares of the company, a new filing with the Securities and Exchange Commission showed. The position is equates to 5.8% of common stock and is passive by nature.

Peter Kolchinsky

Recently, the company completed its initial public offering of 6.90 million common stock shares at a public offering price of $21 per share, which included 900,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares.  The company has a market cap of $676.1 million.

Versartis Inc (NASDAQ:VSAR) is an endocrine-focused biopharmaceutical company initially developing VRS-317, a novel, long-acting form of recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD). VRS-317 is intended to reduce the burden of daily treatment by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes. The company’s first targeted indication for VRS-317 is pediatric GHD, which represents an about $1.5 billion existing market opportunity.

Currently, the company is conducting the Phase 2a stage of its pediatric GHD clinical trial in which it is evaluating the dosing regimens of the drug. The company has global rights to VRS-317 and,  if it is approved, it intends to sell it via its own specialty sales force in the United States and Canada, as well as other regions.

Versartis Inc (NASDAQ:VSAR) is led by co-founder and chief executive officer Jeffrey L. Cleland. Aisling Capital, managed by Dennis Purcell, held a major stake in Versartis Inc (NASDAQ:VSAR) before the IPO, according to another filing.

Boston-based RA Capital invests in companies with promising drugs and technologies. In the beginning of this month, Ra Capital disclosed a new passive stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA), owning 1.54 million shares. Last month, RA Capital revealed initiating a new position in SANUWAVE Health Inc. (OTCBB:SNWV) and raising its stake in pSivida Corp. (NASDAQ:PSDV). In the first company, the fund has reported a 9.9% passive stake, which contains around 4.67 million shares. Also, the fund disclosed a new stake in Repros Therapeutics Inc (NASDAQ:RPRX), holding 1.44 million shares.

Disclosure: none

Recommended Reading:

Anchorage Advisors Sells Over 1 Million Shares In Central Pacific Financial Corp. (CPF)

Jeffrey Smith, Starboard Value are Bullish on Unwired Planet Inc (UPIP)

New Changes in SAC Capital’s 13F Portfolio: Annies Inc (BNNY), Cytokinetics, Inc. (CYTK) And Other

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!